STAT+: Health care providers hope to cash in through Congress’ new earmark process
WASHINGTON — Earmarks are back, and so is the health care industry’s insatiable appetite to…
Category: STAT+
STAT+: Mass. governor’s role in Covid-19 tragedy at the Holyoke Soldiers’ Home
This story first appeared in STAT’s sister publication, the Boston Globe. It was reported by…
STAT+: Freenome, high-profile liquid biopsy company, quietly replaces its CEO
Freenome, a high-profile startup that aims to develop a blood test to detect colon cancer,…
STAT+: Wealthy nations and drug makers offer moves to bridge Covid-19 vaccine divide
The leaders of the world’s wealthiest nations and several drug makers took steps to widen…
STAT+: Pharmalittle: Pfizer and India spar over indemnity for Covid-19 vaccines; J&J to supply Gavi with Covid shots
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Iovance CEO resigns amid a regulatory delay; Republican lawmakers urge Biden to reject Covid-19 IP waiver
Hello, everyone, and how are you today? The sun is shining brightly this morning on…
STAT+: Allogene’s blood cancer data show durability of off-the-shelf CAR-T cells
There’s little disputing that an off-the-shelf CAR-T cell therapy for cancer would provide flexibility and…
STAT+: With new data, J&J’s CAR-T drug benefits myeloma patients with less advanced disease
When doctors prescribe a personalized cell therapy today, the patient they’re trying to help has…
STAT+: In a step forward for immunotherapy, new Bristol Myers drug slows melanoma in study
An experimental immunotherapy developed by Bristol Myers Squibb prevented metastatic melanoma from worsening when added…
STAT+: Merus drug shows potential as treatment for rare type of pancreatic cancer
A drug from the Dutch biotech Merus designed to disrupt a rare genetic alteration is…
STAT+: What’s in a name? Spark Therapeutics sues Bluebird Bio over the use of the word ‘spark’
A promotional campaign has sparked a legal dispute between Spark Therapeutics and Bluebird Bio (BLUE)…
STAT+: Republican lawmakers tell Biden to reverse ‘disastrous decision’ to support Covid-19 IP waiver
Amid a furious debate over boosting global distribution of Covid-19 vaccines, more than a dozen…
STAT+: Iovance CEO abruptly resigns after FDA setback for its cancer cell therapy
Hours after the biotech company Iovance announced yet another regulatory delay for its investigational cancer…
STAT+: Fewer state Medicaid programs are restricting access to hepatitis C medicines, but hurdles remain
Over the past few years, state Medicaid programs have done a better job of disclosing…
STAT+: Emergent was aware of vaccine manufacturing issues even as it collected $27 million a month from U.S.
Under a contract awarded by the Trump administration, Emergent BioSolutions (EBS) was paid $27 million…
STAT+: Pharmalittle: Emergent to be grilled by some House members who received donations; lawmakers ask FTC to probe AbbVie
Rise and shine, everyone, another busy day, and especially so here on the Pharmalot campus,…
STAT+: Health tech companies form a new coalition to advance the role of real-world data
On Wednesday, five health data analytics companies announced they have banded together to form an…
STAT+: As Teladoc bolsters its mental health business, competitors make their case
If Teladoc, the bigfoot of virtual care, comes poking around your turf, you’d better be…
.jpg)
STAT+: Your money or else: Some drug makers could be ‘highly’ susceptible to ransomware attacks
The latest high-profile incident of a ransomware attack caused one of the biggest gas and…
STAT+: Google debuts an AI-powered app to analyze skin conditions
Google on Tuesday debuted an artificial intelligence-powered dermatology tool that analyzes a user’s photos, asks…
STAT+: Atlas Venture launches another biotech to tackle vision loss
Call it “Quest for Sight: The Sequel.” In September, the Swiss drug giant Novartis paid…
STAT+: Pharmalittle: G20 nations water down Covid-19 IP waiver; Biden hopes to grow U.S. share of global vaccine market
Top of the morning to you, and a fine one it is. We enjoy this…
STAT+: How one startup is turning unwieldy health records into a patient-friendly platform
Once seen as the place technological innovation went to die, health records are seeing a…
STAT+: Congress is ready to grill AbbVie’s CEO over drug pricing
WASHINGTON — AbbVie CEO Richard Gonzalez is in for a congressional tongue-lashing of outsized proportion….
STAT+: FDA issues major rebuke to CytoDyn over claims on Covid-19 drug
The Food and Drug Administration on Monday took the extraordinary step of issuing a lengthy…
.jpg)
STAT+: Feds tell drug makers to offer discounts to safety-net hospitals or face penalties
After a year of controversy, the Health Resources and Services Administration notified six large drug…
STAT+: Pharmalittle: Sanofi and Glaxo tout positive Covid-19 vaccine results; Pfizer exec warns IP waiver will cause materials shortage
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Cel-Sci CEO spoke privately with investors last week, raising doubts about long-delayed cancer drug
Cel-Sci CEO Geert Kersten spoke privately with investors last week as part of a “non-deal…
STAT+: Abandoned Trump order on the bioeconomy highlights a path forward for Biden — but with mixed reviews
WASHINGTON — The Trump administration came remarkably close to shoring up the scattershot way the…
STAT+: Pharmalittle: Congress grills U.S. trade representative over Covid-19 IP waiver; Pfizer shot was target of conspiracy theories
Once again, another working week will soon draw to a close. If you are surprised…
STAT+: Charles River loses a battle over harvesting horseshoe crabs used for testing bacteria in drugs
In a setback to Charles River Laboratories (CRL), a federal judge temporarily blocked its contractors…
STAT+: Pharmalittle: Top Emergent execs will testify before Congress; most Americans don’t trust the FDA or CDC
Top of the morning, and a fine one it is. Clear blue skies and crisp…
STAT+: Brazil’s Supreme Court rules that patent extension rules are unconstitutional
The Brazilian Supreme Court ruled that a provision in the country’s intellectual property law allowing…
STAT+: Fibrogen’s data manipulation scandal came with questions. There need to be answers
Fibrogen is reeling from the worst case of data manipulation in years, but six weeks…
Opinion: STAT+: The many benefits of expanding the reach of state all-payer claims databases
Appointments to the newly created State All Payer Claims Databases Advisory Committee in March were…
STAT+: Most Americans believe Biden is correct to support an IP waiver for Covid-19 vaccines
Nearly two in three Americans believe the Biden administration is correct to support a waiver…
STAT+: A clinical trial coordinator is indicted for falsifying data in a Glaxo asthma drug study
A former study coordinator at a company hired to run a clinical trial of a…
STAT+: ‘More Amazon and less pharmacy’: one exec on the company’s strategy for prescription drugs
Amazon’s objectives for its nascent pharmacy business are straightforward: “better selection, better convenience, and better…
STAT+: Watch: Former Google CEO Schmidt opens up on health data privacy and the future of tech in medicine
In a wide-ranging and forthcoming interview, Eric Schmidt, the former Google CEO who helped steer…
STAT+: Ginkgo plans a $17.5 billion merger with SPAC that took DraftKings public
Ginkgo Bioworks, one of the hottest biotech startups in Massachusetts, said Tuesday that it plans…
STAT+: Pharmalittle: Key Dems push Pelosi to seek ‘bipartisan’ drug pricing reform; AstraZeneca CEO pay upsets shareholders
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: Sanofi is accused of ‘widespread destruction’ of company e-mails tied to Zantac recalls
As litigation proceeds over the Zantac heartburn pill and a possible carcinogen, a court filing…
Opinion: STAT+: ‘Induced proximity’ is why I am optimistic about treating undruggable diseases
So-called undruggable proteins — those that supposedly can’t be targeted by pharmaceuticals — represent a…
STAT+: Telehealth companies are fueling a lobbying frenzy to protect their Covid boom
WASHINGTON — Telehealth companies, flush with cash after the Covid-19 pandemic spiked both demand and…
STAT+: Key House Democrats’ push for a ‘bipartisan’ drug pricing bill could doom Pelosi’s signature legislation
WASHINGTON — A group of 10 moderate Democrats is urging House Speaker Nancy Pelosi to…
STAT+: Dana-Farber receives $50 million gift to study pancreatic cancer
Dr. Laurie Glimcher often gets calls from people she knows around the world asking if…
STAT+: Pharmalittle: U.K. says IP waiver is insufficient for Covid-19 vaccine access; EU sues AstraZeneca over vaccine supply — again
Rise and shine, another busy day is on the way. We can tell because our…
STAT+: Inside Pear’s ambitious plan to become the most dominant player in digital therapeutics
In the last six months, Pear Therapeutics has raised $100 million, inked a bevy of new…
STAT+: Dutch advisory group says Zolgensma shouldn’t be covered unless Novartis halves price
In a challenge to Novartis (NVS), a Dutch advisory body has recommended that the government…
STAT+: Flagship startup Laronde hopes to use ‘endless RNA’ to produce new treatments
In 2017, scientists at Flagship Pioneering were exploring different kinds of ribonucleic acid, or RNA,…